This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Research Reports for Tesla, TotalEnergies & Intuitive Surgical
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), TotalEnergies SE (TTE) and Intuitive Surgical, Inc. (ISRG).
The Zacks Analyst Blog Highlights InMode, Johnson & Johnson, Intuitive Surgical and GE HealthCare
by Zacks Equity Research
InMode, Johnson & Johnson, Intuitive Surgical and GE HealthCare are included in this Analyst Blog.
Intuitive Surgical, Inc. (ISRG) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) closed the most recent trading day at $306.90, moving +1.03% from the previous trading session.
Thermo Fisher (TMO) Down 4.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Solid Earnings Fuel Potential Bull Market in Medical Devices
by Indrajit Bandyopadhyay
CNBC's Jim Cramer predicts a booming bull market for medical devices, with positive earnings reports across the space. INMD, JNJ, ISRG and GEHC can emerge as potential winners.
Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Intuitive Surgical (ISRG) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Intuitive Surgical (ISRG) outperforms the industry and the S&P 500 Index due to its strength in robotics.
Should First Trust NASDAQ-100 Equal Weighted ETF (QQEW) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QQEW
3 Healthcare Trends to Ride for Longevity
by Andrew Rocco
Because of their longevity, predictability, and stability, healthcare trends can persist for years. The companies covered today are fundamentally and technically robust stocks currently taking advantage of these trends.
STERIS (STE) Q4 Earnings Beat Estimates, Gross Margin Falls
by Zacks Equity Research
Heading into fiscal 2024, STERIS (STE) expects many of its fiscal 2023 challenges to abate, including procedure volumes and supply chain constraints.
Haemonetics (HAE) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Amid a challenging economic environment, Haemonetics (HAE) delivers impressive fiscal fourth-quarter organic revenues, led by the stellar performance across the Plasma and Hospital business.
Alcon (ALC) Q1 Earnings Surpass Estimates, 23' EPS View Up
by Zacks Equity Research
Alcon (ALC) Q1 revenues were driven by strong consumables and equipment sales.
Here's Why You Should Retain Walgreens Boots (WBA) For Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA) on consistent partnership growth and a strong focus on strategic execution.
Charles River (CRL) Q1 Earnings Top Estimates, View Narrowed
by Zacks Equity Research
Charles River (CRL) registers robust growth in small research models, research model services and the Cell Solutions business.
NuVasive (NUVA) Q1 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
NuVasive's (NUVA) strong sales across the U.S. Spinal Hardware and U.S. Surgical Support businesses instill optimism.
Syneos Health (SYNH) Tops Q1 Earnings, Announces Merger Plan
by Zacks Equity Research
Syneos Health's (SYNH) first-quarter 2023 earnings and revenues beat estimates. The company enters into a definitive merger agreement to be acquired by a private investment consortium.
Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Intuitive Surgical, Inc. (ISRG) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
SmileDirectClub (SDC) Q1 Earnings Miss, Gross Margin Up
by Zacks Equity Research
SmileDirectClub (SDC) Q1 revenues are affected by persistent macroeconomic headwinds.
Exact Sciences (EXAS) Q1 Earnings Top, Sales View Raised
by Zacks Equity Research
The upside in Exact Sciences' (EXAS) screening revenues is primarily coming from broad-based momentum in Cologuard adoption.
Henry Schein (HSIC) Q1 Earnings Miss, Operating Margin Dips
by Zacks Equity Research
Henry Schein's (HSIC) first-quarter results largely reflect lower contributions from the sales of PPE products and COVID-19 test kits.
Omnicell's (OMCL) New Acquisitions Aid Growth, Cost Woes Stay
by Zacks Equity Research
Omnicell (OMCL) remains well-positioned to meet pharmacy and hospital needs, backed by the recent acquisitions and expansion of its advanced services solutions.
Bruker's (BRKR) New Buyout to Advance Digital Transformation
by Zacks Equity Research
Bruker's (BRKR) IDS division expands its unique vendor-agnostic software solutions portfolio by integrating ZONTAL with the Mestrelab Research and Arxspan scientific software solutions.
Here's Why You Should Retain Abbott (ABT) Stock For Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) on continued growth in the core Diagnostics arm.
Teleflex (TFX) Q1 Earnings Top Estimates, 2023 Sales View Up
by Zacks Equity Research
Teleflex (TFX) registers growth across the majority of its businesses, including double-digit increases in interventional and surgical revenues in Q1.
Avanos (AVNS) Q1 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
Despite strength in Avanos' (AVNS) Chronic Care segment, its overall first-quarter results reflect soft performances.